These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24932958)

  • 1. Use of augmentation agents for treating depression: analysis of a psychiatric electronic medical record data set.
    Gersing KR; Sheehan JJ; Burchett B; Zhu L; Bates JA; Baker RA; Kalsekar ID
    Psychiatr Serv; 2014 Aug; 65(8):1062-5. PubMed ID: 24932958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations Between Medication Class and Subsequent Augmentation of Depression Treatment in Privately Insured US Adults.
    Ameli O; Soria-Saucedo R; Smith EG; Cabral HJ; Soley-Bori M; Kazis LE
    J Clin Psychopharmacol; 2017 Jun; 37(3):323-331. PubMed ID: 28338544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.
    Dold M; Bartova L; Kautzky A; Serretti A; Porcelli S; Souery D; Mendlewicz J; Montgomery S; Zohar J; Kasper S
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1305-1313. PubMed ID: 30446357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
    Lin CY; Tsai GE; Wang HS; Wu YH; Chiou CC; Wu VY; Lane HY
    J Clin Psychiatry; 2014 Sep; 75(9):e924-31. PubMed ID: 25295435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
    Bartova L; Fugger G; Dold M; Kautzky A; Swoboda MMM; Rujescu D; Zohar J; Souery D; Mendlewicz J; Montgomery S; Fabbri C; Serretti A; Kasper S
    Int J Neuropsychopharmacol; 2022 Feb; 25(2):118-127. PubMed ID: 34637516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder.
    Papakostas GI
    Essent Psychopharmacol; 2005; 6(4):209-20. PubMed ID: 16041917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
    Bauer M; Thase ME; Liu S; Earley W; Eriksson H
    J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study.
    Han C; Wang SM; Seo HJ; Lee BC; Jeon HJ; Kim W; Kwak KP; Pae CU
    J Psychiatr Res; 2014 Feb; 49():75-82. PubMed ID: 24268719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder.
    Fugger G; Bartova L; Dold M; Fabbri C; Fanelli G; Zanardi R; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 114():110480. PubMed ID: 34826558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine augmentation of antidepressant treatment in elderly patients suffering from depressive symptoms: a retrospective chart review.
    Tadger S; Paleacu D; Barak Y
    Arch Gerontol Geriatr; 2011; 53(1):104-5. PubMed ID: 20678815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
    Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.
    Wright BM; Eiland EH; Lorenz R
    Pharmacotherapy; 2013 Mar; 33(3):344-59. PubMed ID: 23456734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.
    Dold M; Bartova L; Mendlewicz J; Souery D; Serretti A; Porcelli S; Zohar J; Montgomery S; Kasper S
    Acta Psychiatr Scand; 2018 May; 137(5):401-412. PubMed ID: 29492960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS
    Int Clin Psychopharmacol; 2014 Mar; 29(2):116-9. PubMed ID: 24108149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression.
    Goforth HW; Carroll BT
    J Clin Psychopharmacol; 2007 Apr; 27(2):216-7. PubMed ID: 17414252
    [No Abstract]   [Full Text] [Related]  

  • 18. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation strategies in the treatment of major depressive disorder. Clinical considerations with atypical antipsychotic augmentation.
    Gitlin MJ
    CNS Spectr; 2007 Dec; 12(12 Suppl 22):13-5. PubMed ID: 18389929
    [No Abstract]   [Full Text] [Related]  

  • 20. Medication use patterns and two-year outcome in first-admission patients with major depressive disorder with psychotic features.
    Craig TJ; Grossman S; Bromet EJ; Fochtmann LJ; Carlson GA
    Compr Psychiatry; 2007; 48(6):497-503. PubMed ID: 17954133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.